Follow Us
HIV Treatment and Medical Care

Viracept (Nelfinavir)

The Latest

An Overview of Viracept (Nelfinavir) Img

An Overview of Viracept (Nelfinavir)

Brand Name: Viracept Other Name(s): NFV, nelfinavir mesylate Drug Class: Protease Inhibitors


Brand name: Viracept Generic name: nelfinavir, or NFV Class: Protease inhibitor (PI) Manufacturer: ViiV Healthcare,, (877) 844-8872 AWP: $919.44/month for 250 and 625 mg tablets Standard Dose: 1,250 mg taken as either two ...

Nelfinavir (Viracept)

What Is Nelfinavir? Who Should Take Nelfinavir? What About Drug Resistance? How Is Nelfinavir Taken? What Are the Side Effects? How Does Nelfinavir React With Other Drugs? What Is Nelfinavir? Nelfinavir, also called Viracept, is a drug ...

Viracept (Nelfinavir)

Viracept is supplied as light blue, film-coated, capsule-shaped tablets imprinted with "VIRACEPT" on one side and "250 mg" on the other (top). To reduce pill burden, the drug is also available as a 625-mg tablet (bottom). Viracept is also available i...

Bon Appetite -- Using Food to Boost Your Viracept

Using one anti-HIV (antiretrovirals, or ARV) medication to improve or "boost" the amount of drug that gets into your body (pharmacokinetics) is not a new concept. Various combinations of these have been developed and have shown to improve the numbe...


Patient Adherence With Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination With Dual NRTIs

Patient adherence with twice-daily dosing of nelfinavir (NLF) equivalent to non-nucleoside reverse transcriptase inhibitors (NNRTI) when given in combination with dual nucleoside analogues (NRTI) (Poster, ThPeB4991) Authored by A. Luber, J. Mul...


Twice-Daily Viracept Dosing OK'd

Twice-daily dosing of the protease inhibitor Viracept (nelfinavir) for the treatment of HIV infection has been approved by the Food and Drug Administration (FDA). The FDA's action, announced on November 29, 1999, was primarily based on interim resul...


Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity

Based on previous efficacy data on other dual protease inhibitor combinations, this study combining the use of IDV with NFV was undertaken to determine the PK and antiviral activity of the combination that allows for favorable twice daily dosing of I...


AIDS Treatment News January 17, 1997

Contents: 1997 Outlook Nelfinavir: Agouron Announces Expanded Access for Children, a Major New Trial, and Enlarged Expanded Access for Adults Retroviruses Conference: Where to Find Reporting on the Internet Medical Marijuana: Unpublished Feder...


Expanding Information on Nelfinavir, the Next Protease Inhibitor

Nelfinavir is a potent protease inhibitor developed by Agouron Pharmaceuticals. It has been submitted to the FDA for accelerated approval and will be marketed under the brand name "Viracept. " Presentations at the 4th Retrovirus conference summarized...